Alex Balogh

Summary

Affiliation: Cross Cancer Institute
Country: Canada

Publications

  1. ncbi request reprint Upfront double high-dose chemotherapy with DICEP followed by BEAM and autologous stem cell transplantation for poor-prognosis aggressive non-Hodgkin lymphoma
    Douglas A Stewart
    Department of Medicine, Foothills Medical Centre, University of Calgary, AB, Canada T2N 4N2
    Blood 107:4623-7. 2006
  2. ncbi request reprint High-dose mitoxantrone-vinblastine-cyclophosphamide and autologous stem cell transplantation for stage III breast cancer: final results of a prospective multicentre study
    D A Stewart
    Department of Medical Oncology, University of Calgary, Canada
    Ann Oncol 16:1463-8. 2005
  3. doi request reprint Pharmacokinetics and pharmacodynamics of plerixafor in patients with non-Hodgkin lymphoma and multiple myeloma
    Douglas A Stewart
    Department of Oncology and Medicine, Tom Baker Cancer Centre, Calgary, Alberta, Canada
    Biol Blood Marrow Transplant 15:39-46. 2009
  4. doi request reprint pY-STAT3 and p53 expression predict outcome for poor prognosis diffuse large B-cell lymphoma treated with high dose chemotherapy and autologous stem cell transplantation
    Douglas A Stewart
    Department of Oncology and Medicine, University of Calgary and Tom Baker Cancer Centre, Calgary, AB, Canada
    Leuk Lymphoma 50:1276-82. 2009
  5. doi request reprint Double high-dose therapy with dose-intensive cyclophosphamide, etoposide, cisplatin (DICEP) followed by high-dose melphalan and autologous stem cell transplantation for relapsed/refractory Hodgkin lymphoma
    Mona Shafey
    Department of Oncology, Tom Baker Cancer Centre and University of Calgary, Calgary, AB, Canada
    Leuk Lymphoma 53:596-602. 2012
  6. ncbi request reprint In pursuit of an artful death: discussion of resuscitation status on an inpatient radiation oncology service
    Alysa Fairchild
    Department of Radiation Oncology, Cross Cancer Institute, Edmonton, Alberta, Canada, T6G 1Z2
    Support Care Cancer 13:842-9. 2005
  7. ncbi request reprint Electronic compensation using multileaf collimation for involved field radiation to the neck and mediastinum in non-Hodgkin's lymphoma and Hodgkin's lymphoma
    Shelly MacDonald
    Department of Medical Physics, Tom Baker Cancer Centre, Calgary, Alberta, Canada
    Med Dosim 30:59-64. 2005

Collaborators

Detail Information

Publications7

  1. ncbi request reprint Upfront double high-dose chemotherapy with DICEP followed by BEAM and autologous stem cell transplantation for poor-prognosis aggressive non-Hodgkin lymphoma
    Douglas A Stewart
    Department of Medicine, Foothills Medical Centre, University of Calgary, AB, Canada T2N 4N2
    Blood 107:4623-7. 2006
    ..In conclusion, CHOP-DICEP-BEAM is feasible and gave encouraging EFS and OS for patients with poor-prognosis aggressive NHL...
  2. ncbi request reprint High-dose mitoxantrone-vinblastine-cyclophosphamide and autologous stem cell transplantation for stage III breast cancer: final results of a prospective multicentre study
    D A Stewart
    Department of Medical Oncology, University of Calgary, Canada
    Ann Oncol 16:1463-8. 2005
    ..High-dose alkylator chemotherapy does not further improve outcome. This phase II study evaluated a novel high-dose chemotherapy regimen which combined active breast cancer agents with differing mechanisms of action...
  3. doi request reprint Pharmacokinetics and pharmacodynamics of plerixafor in patients with non-Hodgkin lymphoma and multiple myeloma
    Douglas A Stewart
    Department of Oncology and Medicine, Tom Baker Cancer Centre, Calgary, Alberta, Canada
    Biol Blood Marrow Transplant 15:39-46. 2009
    ..Plerixafor was safe and effective in mobilizing CD34(+) cells for transplantation...
  4. doi request reprint pY-STAT3 and p53 expression predict outcome for poor prognosis diffuse large B-cell lymphoma treated with high dose chemotherapy and autologous stem cell transplantation
    Douglas A Stewart
    Department of Oncology and Medicine, University of Calgary and Tom Baker Cancer Centre, Calgary, AB, Canada
    Leuk Lymphoma 50:1276-82. 2009
    ..0002). In conclusion, pY-STAT3 and p53 expression may help predict outcome of HDCT for DLBCL, and further study of these biomarkers is warranted...
  5. doi request reprint Double high-dose therapy with dose-intensive cyclophosphamide, etoposide, cisplatin (DICEP) followed by high-dose melphalan and autologous stem cell transplantation for relapsed/refractory Hodgkin lymphoma
    Mona Shafey
    Department of Oncology, Tom Baker Cancer Centre and University of Calgary, Calgary, AB, Canada
    Leuk Lymphoma 53:596-602. 2012
    ..In conclusion, DICEP-HDM/ASCT is well tolerated double high-dose therapy associated with excellent stem cell mobilization and favorable PFS and OS outcomes for relapsed as well as primary refractory HL...
  6. ncbi request reprint In pursuit of an artful death: discussion of resuscitation status on an inpatient radiation oncology service
    Alysa Fairchild
    Department of Radiation Oncology, Cross Cancer Institute, Edmonton, Alberta, Canada, T6G 1Z2
    Support Care Cancer 13:842-9. 2005
    ..We performed a quality assurance investigation on the use of the 'do-not-resuscitate' (DNR) order on an inpatient radiation oncology service to determine how often DNR orders are accompanied by a description of informed consent...
  7. ncbi request reprint Electronic compensation using multileaf collimation for involved field radiation to the neck and mediastinum in non-Hodgkin's lymphoma and Hodgkin's lymphoma
    Shelly MacDonald
    Department of Medical Physics, Tom Baker Cancer Centre, Calgary, Alberta, Canada
    Med Dosim 30:59-64. 2005
    ..Thermoluminescent dosimeters (TLDs) have verified point-dose uniformity noticeably to +/- 5%. An efficient technique using forward planning for simple IMRT consisting of static MLC and asymmetric jaws has been developed...